Gilead has become the latest pharma to strengthen its in-vivo cell therapy credentials this year, paying $350 million for CAR-T developer Interius BioTherapeutics. | Gilead has become the latest ...

Gilead will integrate Interius, the first biotech to push an in vivo CAR-T therapy into the clinic, into its cell therapy ...

Kite has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately held company developing in vivo CAR therapeutics.

Gilead Sciences' unit Kite Pharma said on Thursday it will acquire privately-held biotech firm Interius BioTherapeutics for ...

Gilead subsidiary Kite Pharma said that it has acquired Interius BioTherapeutics and its single-shot CAR-T program for $350 million.

Kite Pharma is acquiring Interius BioTherapeutics for $350 million, adding in vivo CAR T technology that could simplify treatment and expand patient access.

The acquisition aims to expand Kite Pharma’s capabilities in in vivo CAR T-cell therapy research and development.

Interius is working on a more efficient way to deliver CAR-T therapy to patients. Unlock Digital Access for unlimited access to Inquirer.com and The Inquirer App, plus 5 articles per month to gift to ...

Kite's technology is impressive but it is new and unproven. However, risk and uncertainty are inherent in Gilead's business. I consider that this deal has been a long time coming.

Gilead’s acquisition of Kite has not only spurred on the current biotech bull market, but it should also beget other M&A activity as immunotherapy enters hyper-drive, animating companies like ...

Gilead is to pay $180 in cash for each share of Kite Pharma, a 29% premium over the Friday closing price. Kite Pharma stock leaped 28% to $178.05 on Monday. Gilead shares rose about 1% to $74.69.

Kite, a Gilead Company, is a biopharmaceutical company based in Santa Monica, California. Kite is engaged in the development of innovative cancer immunotherapies.